Liquidation: AN2 Therapeutics, Inc.

Form Type: SCHEDULE 13D

Filing Date: 2025-05-07

Corporate Action: Liquidation

Type: New

Accession Number: 000137360425000074

Filing Summary: On May 7, 2025, BML Investment Partners, L.P. filed a Schedule 13D regarding its ownership of AN2 Therapeutics, Inc., holding 5,749,432 shares, representing 19.1% of the company's common stock. The document reveals that the shares were acquired for investment purposes. The filing includes a letter addressed to the Board of Directors expressing the belief that an orderly winddown, liquidation, and capital return is in the best interests of the shareholders. BML Investment Partners has not engaged in any transactions involving the company's common stock for 60 days prior to the filing. Neither BML Investment Partners nor its managing member, Braden M. Leonard, has any legal issues or plans for the company that would lead to actions described in Item 4 of Schedule 13D.